Popular Design for Lemborexant - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex
Popular Design for Lemborexant - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:
Product Detail
| Name | Desmopressin |
| CAS number | 16679-58-6 |
| Molecular formula | C46H64N14O12S2 |
| Molecular weight | 1069.22 |
| EINECS Number | 240-726-7 |
| Specific rotation | D25 +85.5 ± 2° (calculated for the free peptide) |
| Density | 1.56±0.1 g/cm3(Predicted) |
| RTECS No. | YW9000000 |
| Storage conditions | Store at 0°C |
| Solubility | H2O:soluble20mg/mL, clear, colorless |
| Acidity coefficient | (pKa) 9.90±0.15 (Predicted) |
Synonyms
MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN
Indications
(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.
(2) Treatment of nocturnal enuresis (patients aged 5 years or older).
(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.
(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.
Treatment of diabetes insipidus
Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.
Product detail pictures:
Related Product Guide:
We constantly believe that one's character decides products' high quality, the details decides products' high-quality ,together with the REALISTIC,EFFICIENT AND INNOVATIVE crew spirit for Popular Design for Lemborexant - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: Chicago, Angola, European, Certainly, competitive price, suitable package and timely delivery will be assured as per customers' demands. We sincerely hope to build business relationship with you on the basis of mutual benefit and profit in the very near future. Warmly welcome to contact us and become our direct cooperators.
By Sara from Belgium - 2018.11.22 12:28
With a positive attitude of "regard the market, regard the custom, regard the science", the company works actively to do research and development. Hope we have a future business relationships and achieving mutual success.
By Dee Lopez from Colombia - 2018.12.28 15:18
